Performance of the 2017 EULAR/ACR Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a scoping review
Year: 2023
Type: article
Study design: Systematic Review
Abstract: The 2017 EULAR/ACR classification criteria for adult/juvenile idiopathic inflammatory myopathies (IIM) were established using a data-driven approach by an international group of myositis experts to allow classification of IIM and its major subtypes. Since their publication, the performance of the criteria has been tested in multiple cohorts worldwide and significant limitations have been identified. Moreover, the understanding and classification of IIM have evolved since 2017. This scoping review was undertaken as part of a large international project to revise the EULAR/ACR criteria and aims to i) summarise the evidence from the current literature on the performance characteristics of the 2017 EULAR/ACR classification criteria in various cohorts and IIM subtypes, and ii) delineate the factors that need to be considered in the revision of the classification criteria. A systematic search of Medline (via PubMed), Cumulative Index to Nursing and Allied Health Literature, and conference abstract archives was conducted independently by three investigators for studies on the EULAR/ACR criteria published between October 2017 and January 2023. This scoping review of 19 articles and 13 abstracts revealed overall good performance characteristics of the EULAR/ACR criteria for IIM, yet deficiencies in lack of inclusion of certain IIM subtypes, such as immune mediated necrotising myopathy, amyopathic dermatomyositis, antisynthetase syndrome and overlap myositis. Published modifications that may improve the performance characteristics of the criteria for classification of IIM subtypes were also summarised. The results of this review suggest that a revision of the EULAR/ACR criteria is warranted.
Authors: Didem Saygin, Stefanie Glaubitz, Rachel Zeng, Matteo Bottai, Marianne de Visser, Mazen M. Dimachkie, David Fiorentino, Ingrid Gerhardson, Masataka Kuwana, Frederick W. Miller, Merrilee Needham, Lisa G. Rider, Yasser Salem, Silke Schlüter, Samuel K. Shinjo, Guochun Wang, Victoria P. Werth, Rohit Aggarwal, Ingrid E. Lundberg
Institutions: Novartis (Switzerland), University of Pittsburgh, Universitätsmedizin Göttingen, Karolinska Institutet, Amsterdam Neuroscience, Amsterdam University Medical Centers, University of Amsterdam, University of Kansas Medical Center, Stanford Medicine, Stanford University, Nippon Medical School, National Institutes of Health, National Institute of Environmental Health Sciences, Murdoch University, Fiona Stanley Hospital, Hofstra University, Deutsche Gesellschaft für Muskelkranke, Universidade de São Paulo, China-Japan Friendship Hospital, Philadelphia VA Medical Center, University of Pennsylvania, Karolinska University Hospital
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, University of Pennsylvania, University of Notre Dame, CSL Behring, Regeneron Pharmaceuticals, Sarepta Therapeutics, Amicus Therapeutics, Myositis Association, Argenx, Amsterdam University Medical Centers, Murdoch University, Universiteit van Amsterdam, Karolinska Institutet, Vetenskapsrådet, Universidade de São Paulo, Faculdade de Medicina da Universidade de São Paulo, Reumatikerförbundet, Deutsche Gesellschaft für Muskelkranke, Mitsubishi Tanabe Pharma Corporation, Grifols, Fiona Stanley Hospital, Amsterdam Neuroscience, National Institutes of Health, Genentech, EMD Serono, School of Medicine, Stanford University, Perelman School of Medicine, University of Pennsylvania, Sanofi Genzyme, Spark Therapeutics, China-Japan Friendship Hospital, National Institute of Arthritis and Musculoskeletal and Skin Diseases
OpenAlex ID: W4392411191